text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 169590-42-5 | Product Number: C2816


Purity: >98.0%(T)(HPLC)
  • 5-(4-Methylphenyl)-1-(4-sulfamoylphenyl)-3-(trifluoromethyl)pyrazole
  • 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide
4   ≥20 
10   ≥20 

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).

Product Number C2816
Purity / Analysis Method >98.0%(T)(HPLC)
Molecular Formula / Molecular Weight C__1__7H__1__4F__3N__3O__2S = 381.37  
Physical State (20 deg.C) Solid
CAS RN 169590-42-5
Reaxys Registry Number 7662430
PubChem Substance ID 253660758
Merck Index (14) 1956
MDL Number


Appearance White to Almost white powder to crystal
Purity(HPLC) min. 98.0 area%
Purity(Neutralization titration) min. 98.0 %
Melting point 161.0 to 165.0 °C
Properties (reference)
Melting Point 163 °C
Solubility in water Insoluble
Solubility (very soluble in) Methanol
Solubility (soluble in) Ethanol
Pictogram Pictogram
Signal Word Warning
Hazard Statements H361 : Suspected of damaging fertility or the unborn child.
H373 : May cause damage to organs through prolonged or repeated exposure.
Precautionary Statements P501 : Dispose of contents/ container to an approved waste disposal plant.
P260 : Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.
P202 : Do not handle until all safety precautions have been read and understood.
P201 : Obtain special instructions before use.
P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection.
P308 + P313 : IF exposed or concerned: Get medical advice/ attention.
Related Laws: / Compliance with laws, Regulations
RTECS# DB2944937
Transport Information:
HS Number 2935909099
Celecoxib: A Selective Cyclo-Oxygenase-2 (COX-2) Inhibitor

Celecoxib (SC-58635), a nonsteroidal anti-inflammatory drug (NSAID), is a cyclo-oxygenase (COX) inhibitor that exhibits relative selectivity for COX-2 over COX-1 in vitro and in vivo. In theory, a drug such as celecoxib that selectively inhibited COX-2 might block inflammation, pain, and fever produced by prostaglandins while reducing the side effects (gastric erosions and ulcers) associated with inhibition of COX-1. In addition, celecoxib is reported that has anticancer properties.


PubMed Literature

Safety Data Sheet (SDS) Search
Please select Language.

The requested SDS is not available.

• Please check that the Product Number you have entered is correct.

• If your information is correct and you are still not able to view the requested SDS,  please Contact Us for more information.

C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number is entered
Other Documents